Epzicom (abacavir/lamivudine) Alcohol, Food & Lifestyle Interactions

There are 2 food and lifestyle interactions with Epzicom (abacavir/lamivudine) which include:

Consumption of ethanol during treatment with abacavir results in a decrease in elimination of abacavir due to the inhibition of alcohol dehydrogenase. Coadministration of alcohol 0.7 g/kg (equivalent to 5 drinks) and abacavir resulted in a 41% increase in the area under the time concentration curve and a 26% increase in elimination half life. The clinical significance of this interaction is unknown.

NRTIs - pancreatitis

The reverse transcriptase inhibitors, didanosine (ddI), zalcitabine (ddC), stavudine (d4T) and lamivudine (3TC), may cause pancreatitis. The incidence is generally low but is approximately 7% with ddI, and up to 15% in pediatric patients given 3TC. Patients with a history of or known risk factors for pancreatitis, such as alcohol abuse or hypertriglyceridemia, should be monitored closely during therapy with these agents. Therapy should be discontinued at the first signs or symptoms suggestive of pancreatitis (e.g., nausea, vomiting, abdominal pain, hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium), and preferably permanently discontinued if clinical pancreatitis develops.

You should also know about...

Epzicom (abacavir/lamivudine) drug Interactions

There are 26 drug interactions with Epzicom (abacavir/lamivudine)

Epzicom (abacavir/lamivudine) disease Interactions

There are 3 disease interactions with Epzicom (abacavir/lamivudine) which include:

Hepatotoxicity Pancreatitis

Renal Dysfunction

See also...

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2009 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.